Recent breakthrough results from immune checkpoint inhibitors (ICI) such as an anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA4) monoclonal antibody (mAb) (ipilimumab) and antiprogrammed cell death-1 (anti-PD-1) mAbs (nivolumab and pembrolizumab) have paved the way to a new era of cancer immunotherapy, leading to a paradigm shift in cancer treatment. Currently, ICI has had immense clinical success resulting in sustained treatment response for a subset of cancer patients such as melanoma, non-small-cell lung cancer, urothelial carcinoma, squamous cell carcinoma of the head and neck, renal cell cancer, gastric cancer, and hepatocellular cancer.
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Taken together, so far, anti-PD1 mAb is a key drug for immunotherapy for gastroenterological malignance. We can select responder patients for ICI based on biomarker profile using genome
